Physician profile
David C Ludwig
NPI 1629034970
$3,598.06
in general payments reported to CMS, 2019-2025
29 companies · $593 in 2025
The $593 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $824 · 2020: $99.95 · 2021: $115 · 2022: $766 · 2023: $652 · 2024: $549 · 2025: $593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,794.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,793.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $745.61 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $537.97 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $423.23 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $404.44 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $179.85 | 2019-2024 | Spravato |
| Glaxosmithkline, LLC. | $139.37 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $133.80 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.96 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $94.02 | 2019-2025 | Veozah |
| Abbott Laboratories | $89.23 | 2022-2025 | Freestyle Libre 2 |
| E.R. Squibb & Sons, L.L.C. | $87.67 | 2025 | Camzyos, Eliquis |
| Exact Sciences Corporation | $77.96 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Kowa Pharmaceuticals America, INC. | $65.35 | 2019-2025 | Zoryve |
| Abbvie INC. | $63.94 | 2022-2025 | |
| Amgen INC. | $54.48 | 2024 | Otezla, Repatha, Krystexxa |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vbi Vaccine (Delaware) INC. | $46.26 | 2022-2023 | Prehevbrio |
| Amarin Pharma, INC. | $43.48 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $39.61 | 2023-2024 | Gvoke Hypopen |
| Nevro Corp. | $36.43 | 2022-2023 | Senza |
| Dexcom, INC. | $31.22 | 2024 | Dexcom G6 Transmitter |
| Hikma Pharmaceuticals USA | $30.88 | 2019 | |
| Coloplast Corp | $30.18 | 2019 | |
| Sanofi-Aventis U.S. LLC | $30.11 | 2019 | |
| Shire North American Group INC | $27.30 | 2019 | |
| Genentech USA, INC. | $18.01 | 2019 | |
| Si-Bone, INC. | $15.00 | 2023 | |
| Allergan, INC. | $14.00 | 2019 | |
| Merck Sharp & Dohme LLC | $13.12 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Ludwig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.